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Abstract
Background: Obesity is a known risk factor for colorectal cancer (CRC), and emerging data suggest that this association is
mediated by visceral fat rather than total body fat. However, there is a lack of studies evaluating the association between
visceral fat area and the prevalence of CRC.
Methods: To investigate the relationship between visceral adiposity and prevalence of CRC, data of 497 women diagnosed
with CRC and 318 apparently healthy women were analysed and data of well-balanced 191 pairs of women with CRC and
healthy women matched based on propensity scores were additionally analysed. Diagnosis of CRC was confirmed by
colonoscopy and histology. Metabolic parameters were assessed, along with body composition, using computed
tomography.
Results: The median visceral fat area was significantly higher in the CRC group compared with the control group before and
after matching. The prevalence of CRC increased significantly with increasing visceral fat tertiles after matching (p for trend
,0.01). A multivariate analysis showed that mean visceral fat area of individuals in the 67th percentile or greater group was
associated with an increased prevalence of CRC (adjusted odds ratio: 1.80; 95% confidence interval: 1.12–2.91 before
matching and adjusted odds ratio: 2.96; 95% confidence interval: 1.38–6.33) compared with that of individuals in the 33th
percentile or lower group.
Conclusion: Thus, we conclude that visceral fat area is positively associated with the prevalence of CRC. Although we could
not determine the causality, visceral adiposity may be associated with the risk of CRC. Further prospective studies are
required to determine the benefits of controlling visceral obesity for reducing CRC risk.
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Introduction
Obesity and cancer are emerging as two of the most serious
health problems worldwide. Obesity is known to increase the risk
of cardio-metabolic diseases including Type 2 diabetes mellitus
(DM), cardiovascular disease, and metabolic syndrome [1,2].
Furthermore, the relationship between obesity and several types of
cancer such as renal, oesophageal, colorectal, and breast cancer
has also been reported [3,4]. The precise underlying mechanism
that explains how obesity promotes these diseases is still unclear;
however, recent evidence suggests that visceral adipose tissue may
play a key role in this relationship. Visceral adipose tissue, largely
distributed in the abdominal cavity, shows higher hormonal and
metabolic activities than subcutaneous fat tissue [5]. Visceral
adipocyte-secreted growth factors, proinflammatory cytokines, and
adipokines are considered mediating factors associated with the
carcinogenesis of obesity-related tumours [6].
Colorectal cancer (CRC) is well known as an ‘obesity-related’
cancer. Recent epidemiologic studies have shown that waist
circumference or the waist-hip ratio, which reflect abdominal
adiposity rather than total body mass index (BMI), showed greater
association with increased risk of CRC [7–9]. These findings
indicate that the regional distribution of adipose tissue, not overall
adiposity, may contribute to the increased risk of CRC. Altered
metabolic activity and systemic chronic inflammation induced by
visceral adipose tissue are also considered to be related with
colorectal carcinogenesis [10]. A few studies have assessed the
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relationship between CRC risk and visceral obesity using a direct
method to measure visceral fat area; however, the results were
inconclusive [11–13]. Some studies showed increased CRC risk
with higher visceral adipose tissue accumulation. However, no
significant relationship, and even opposing results, have been
reported.
Therefore, we investigated the relationship between the
prevalence of CRC and visceral fat area by comparing a colorectal
cancer group and a case-matched control group of Korean
women.
Methods
Ethical statement
All subjects participated in the study voluntarily, and written
informed consent was obtained from each participant. The study
complied with the Declaration of Helsinki, and the Institutional
Review Board of Yonsei University College of Medicine approved
this study.
Study subjects
The study subjects consisted of 1920 postmenopausal women
who visited the Department of Colorectal Surgery and were
diagnosed with CRC during their visit and 670 postmenopausal
women who visited the Health Promotion Centre and the
Department of Family Medicine at Severance Hospital for routine
health check-ups that included a screening colonoscopy between
November 2010 and August 2012. Menopausal status was defined
as having had no menstrual periods for 12 consecutive months
without any biological or physiological cause. We excluded women
who were taking medication for a diagnosis of hypertension,
diabetes mellitus, chronic liver disease, chronic renal disease,
coronary artery occlusive disease, or stroke. We also excluded
women who underwent polyp removal procedures or who were
diagnosed with CRC or other types of cancer prior to their
participation in the study. After applying the exclusion criteria, a
total of 497 women diagnosed with CRC were defined as the CRC
group, and 318 apparently healthy women were defined as the
control group. From the CRC and healthy groups, a well-balanced
study population consisting of 199 pairs of women was selected by
propensity score matching.
Measurement of clinical parameters
All subjects completed a questionnaire about their lifestyle, such
as smoking, alcohol consumption, regular exercise, underlying
medical conditions, and medications. Cigarette smoking was
defined as current or past smokers, and alcohol consumption
was defined as drinking alcohol more frequently than once per
week or more than 70 grams per week during the previous year.
Blood pressure was measured in the sitting position after the
subject was asked to rest for longer than 10 minutes. The mean
blood pressure (mmHg) was calculated using the systolic blood
pressure (SBP) and diastolic blood pressure (DBP) as follows:
(SBP+2XDBP)/3. Body mass index (BMI) was defined as weight
(kg) divided by height squared (m2).
Blood samples were collected after at least 8 hours of fasting.
Fasting glucose, aspartate aminotransferase (AST), alanine ami-
notransferase (ALT), creatinine, and total cholesterol levels were
measured by using the Hitachi 7600 Automatic analyzer (High-
Technologies Corporation, Hitachi, Tokyo, Japan). White blood
cell (WBC) counts were measured using an automated blood cell
counter (ADVIA 120, Bayer, NY, USA). The biomarkers were
part of the routine tests for patients who were planning to receive
CRC surgery. The control group also have received the same
blood tests as a part of their routine health check-ups.
Assessment of body composition
Abdominal fat tissue areas were measured by computed
tomography (Tomoscan 350; Philips, Mahwah, NJ, USA) as
described previously [14]. A single cross-sectional CT image of a
3-mm thick slice at the level of L4–L5 interspace was obtained
with the subject in a supine position. The visceral and
subcutaneous fat areas were calculated at this slice using a
commercially available software program (TeraRecon Aquarius;
TeraRecon, CA, USA), which determined the fat area electron-
ically by setting the attenuation range from 2150 to 250
Hounsfield units. Visceral adipose tissue areas were measured by
delineating the intra-abdominal cavity at the internal aspect of the
abdominal and oblique muscle walls surrounding the cavity and
the posterior aspect of the vertebral body. The subcutaneous
adipose tissue area was calculated by subtracting the VAT area
from the total adipose tissue area. All measurements were
performed by a skilled radiologist who was blinded to the patient
data. The inter- and intra-coefficients of variation (CVs) for
reproducibility were 1?4% and 0?5%, respectively.
Diagnosis of CRC
All participants received colonoscopic examinations performed
by experienced gastroenterologists after bowel preparation with 4
litres of polyethylene glycol solution (Colyte; Taejun, Seoul,
Korea). All procedures were performed by using a standard video
colonoscope (CFQ240L, Olympus, Optical, Tokyo, Japan).
Biopsies were taken from all detected suspicious lesions, and the
final diagnosis of CRC was made by histopathological analysis.
CRC was diagnosed if malignant cells were observed above the
muscularis mucosae. The classification system recommended by
the American Joint Committee on Cancer (AJCC) was used for
tumour staging [15]. The locations of the tumours were recorded
and divided into sigmoid, ascending, transverse, and descending
colon, and rectum.
Statistical analyses
Data for demographic characteristics are represented as the
mean6 standard deviation or number (%). To reduce the effect of
confounding factors that may affect the relationship between CRC
and visceral adiposity, we adjusted for differences in the clinical
basal characteristics between the CRC and control groups using
propensity score matching [16]. The demographic characteristics
of the CRC and control groups before matching were compared
using two-sample t-tests for continuous data and Chi-square tests
or Fisher’s exact tests for categorical data. All variables constitut-
ing baseline demographic characteristics, such as age, BMI,
smoking status, alcohol consumption, and regular exercise, were
included as exact matching factors. A propensity score for the
predicted probability of cancer in each woman was estimated
using a logistic regression model fit with five factors. The controls
were matched 1:1 with CRC patients. A nearest-neighbour-
matching algorithm with a greedy heuristic was used to match
patients for demographic characteristics. The matched demo-
graphic characteristics of the CRC and control groups were
compared using paired t-tests for continuous data and McNemar
tests for categorical data. The metabolic parameters were
described as median and interquartile range, and differences
between the two groups after matching were compared using
Wilcoxon signed-rank tests.
Tertiles were categorized as follows based on visceral fat areas:
Q1: ,67.98 cm2, Q2: 67.98–91.67 cm2, Q3: .91.67 cm2. The
Visceral Fat and Colorectal Cancer
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prevalence of CRC according to the visceral fat tertiles was
compared using the Cochran-Armitage trend test. The odds ratio
and 95% confidence intervals (CI) for CRC were calculated using
conditional logistic regression analyses after adjusting for con-
founding factors across visceral fat tertiles.
All statistical analyses were performed using SAS software
version 9.2 (SAS Institute Inc., Cary, NC, USA).
Results
Characteristics of the study population
The clinical characteristics of the CRC and control groups
before and after propensity score matching are given in Table 1.
Women with CRC showed a significantly higher age and lower
BMI, and lower incidence of regular exercise. After propensity
score matching was completed, there were 199 matched pairs of
participants. There were no significant differences in clinical
characteristics between the two groups.
Table 2 shows the metabolic parameters of the CRC and
control groups before and after matching. Visceral fat area,
visceral/subcutaneous fat ratio, mean blood pressure, fasting
glucose levels, WBC count, and creatinine levels were significantly
higher in the CRC group compared to the control group before
and after matching (p,0.05). The subcutaneous fat area was
significantly lower in the CRC group compared to the control
group before and after matching (p,0.05). ALT levels were
significantly higher in the control group only before matching
(p,0.01)
Characteristics of colorectal neoplasms
Table 3 describes the stage and location of the tumours in the
CRC group before after matching. Categorization of patients
according to cancer stage at first diagnosis revealed that 15.49%
(n= 77) of patients were stage I, 24.55% (n= 122) were stage II,
25.15% (n= 125) were stage III, and 34.81% (n= 173) were stage
IV before matching. After propensity score matching, 16.58%
(n= 33) of patients were stage I, 24.12% (n= 48) were stage II,
23.12% (n= 46) were stage III, and 36.18% (n= 72) were stage IV.
Of these, 276 (55.53%) patients had a tumour in the colon and 221
(44.47%) had a tumour in the rectum before matching and 113
(56.78%) patients had a tumour in the colon, and 86 patients
(43.22%) had a tumour in the rectum after matching.
The prevalence of CRC based on visceral fat area tertiles
The prevalence values of CRC based on the 3 visceral fat area
tertiles (Q1, Q2, and Q3) were shown in Figure 1. Before
matching, the prevalence values of CRC based on the 3 visceral fat
area tertiles (Q1, Q2, and Q3) were 54.24%, 54.21%, and
74.54%, respectively (P,0.01, Figure 1A). After matching the
prevalence of CRC increased significantly according to the visceral
fat tertiles. (30.77%, 45.76% and 69.49%, respectively (P,0.01).
(Figure 1B)
Table 4 and 5 shows the odds ratio of the prevalence of CRC
based on the visceral fat area tertiles before and after propensity
score matching. The multivariate-adjusted odds ratio (95% CI) for
the highest versus the lowest visceral fat tertiles were 1.80 (1.19–
2.91) (unmatched) and 2.96 (1.38–6.33) (matched) after adjusting
for subcutaneous fat area, mean blood pressure, WBC counts,
fasting glucose, total cholesterol, creatinine, AST, and ALT levels.
These positive associations persisted even after separating the
prevalence of cancer into colon (OR 3.47, CI; 1.24–9.68) or
rectum (OR 4.15, CI; 1.05–16.34) sites in propensity score
matching group. These positive associations also persisted after
separating the group according to cancer stage as stage I, II (OR
3.64, CI; 1.41–9.39) and stage III, IV (OR 3.80, CI; 1.39–10.40)
in propensity score matching group.
Discussion
Our cross-sectional study revealed a positive relationship
between abdominal visceral obesity and CRC in Korean women.
Visceral fat areas in the third tertile were associated with an
approximately three times higher prevalence of CRC compared
with areas in the first tertile after propensity score matching and
adjusting for confounding factors (odds ratio: 2.96; 95% CI: 1.38–
6.33). Furthermore, this association persisted after separating the
cancer sites and stages.
The prevalence of CRC has rapidly increased in the past 20
years in conjunction with the increasing prevalence of obesity
worldwide [3]. Obesity is known to increase the risk of CRC
significantly [10,17] and is also related with poor prognosis after
treatment [18]. Recent studies have demonstrated the important
role of visceral adiposity rather than general obesity in colorectal
carcinogenesis [7–9]. However, these studies assessed CRC risk
through direct measurement of visceral fat area using CT and
provided conflicting results. Recent clinical studies have shown a
significant association between CRC and visceral fat area. [11,12].
Table 1. Comparison of demographic characteristics between the control group and the colorectal cancer group before and after
propensity score matching.
Unmatched Matched
Control (n =318) Cancer (n =497) P-value a Control (n = 199) Cancer (n=199) P-value b
Age 58.3869.84 60.70612.29 ,0.01 60.7368.55 60.7368.55 ..99
BMI (kg/m2) 23.9162.39 23.463.55 0.02 23.8462.42 23.5663.18 ..99
Smoking status (yes) (%) 11(3.46) 13(2.62) 0.49 2(1.01) 2(1.01) ..99
Alcohol consumption (yes) (%) 21(6.60) 20(4.02) 0.10 2(1.01) 2(1.01) ..99
Regular exercise (yes) (%) 82(25.79) 34(6.84) ,.001 9(4.52) 9(4.52) ..99
Normality was tested by the Kolmogorov-Smirnov test.
Data are the mean6 standard deviation or percentage.
aP - values were derived from an independent-sample t-test for continuous data, and Chi-square test was performed for categorical data.
bP - values were derived from a paired t-test for parametric data or the McNemar test for categorical data.
Abbreviation: BMI, body mass index.
doi:10.1371/journal.pone.0110587.t001
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However, opposing results have also been reported. [13]. A small
sample size, the confounding effect of unequal clinical character-
istics of the participants, and the effect of tumour-related weight
loss prior to the measurement of visceral fat are the factors that
likely contributed to these unexpected results. In the present study,
all of the participants underwent colonoscopy in the same hospital,
and demographic characteristics between the control and CRC
groups were carefully matched to reduce the effect of potential
confounding factors. To our knowledge, this is the first study to
compare the association between the prevalence of CRC and
visceral fat area in confounding characteristics-matched cohorts.
Table 2. Comparison of metabolic parameters between the control group and the colorectal cancer group before and after
propensity score matching.
Unmatched Matched
Control (n =318) Cancer (n =497) P-value a Control (n = 199) Cancer (n =199) P-value a
Visceral fat area (cm2) 74.02(24.58–246.04) 88.2(19.3–256.2) ,0.01 73.47(24.58–246.04) 87.2(19.3–231.3) ,0.01
Subcutaneous fat area (cm2) 209.4(48.09–437.09) 189.5(22.8–445.2) ,0.01 205.79(48.09–394.44) 195.1(81.4–445.2) 0.02
Visceral/Subcutaneous Fat ratio (%) 0.35(0.09–2.04) 0.45(0.14–1.72) ,0.01 0.34(0.09–2.04) 0.44(0.18–1.14) ,0.01
Mean blood pressure (mmHg) b 86.67(67–117) 89.33(65.67–136) ,0.01 86.67(67–117) 90.33(68.33–121.67) ,0.01
Fasting glucose (mg/dl) 90(64–170) 98(69–384) ,0.01 90(64–170) 100(69–326) ,0.01
Total cholesterol (mg/dl) 183(100–270) 182(76–333) 0.57 178(100–270) 188(80–285) 0.36
WBC (counts/L) 5475(2760–9770) 6405(1020–23940) ,0.01 5500(2760–9770) 6350(1020–23940) ,0.01
Creatinine (mg/dL) 0.73(0.41–7.01) 0.75(0–2.6) ,0.01 0.73(0.41–6.73) 0.74(0–1.56) 0.04
AST (U/L) 18(8–75) 18(4–166) 0.14 18(8–75) 18(4–94) 0.14
ALT (U/L) 16(7–167) 14(0–218) ,0.01 16(7–167) 14(5–100) 0.10
aP - values were derived using the Wilcoxon signed rank test.
Data are the median (25–75 percentile range).
bThe mean blood pressure (mmHg) was calculated using the systolic blood pressure (SBP) and diastolic blood pressure (DBP) as follows: (SBP+2XDBP)/3.
Abbreviation: WBC, white blood cell; AST, aspartate aminotransferase; ALT, alanine aminotransferase.
doi:10.1371/journal.pone.0110587.t002
Table 3. Clinical features of the colorectal cancer patients after propensity score matching.
No. %
Before propensity score matching
Stage of tumour I 77 15.49
II 122 24.55
III 125 25.15
IV 173 34.81
Location Colon 276 55.53
Sigmoid 138 27.77
Ascending 87 17.51
Transverse 20 4.02
Descending 31 6.24
Rectum 221 44.47
After propensity score matching
Stage of tumour I 33 16.58
II 48 24.12
III 46 23.12
IV 72 36.18
Location Colon 113 56.78
Sigmoid 50 25.13
Ascending 39 19.60
Transverse 9 4.52
Descending 15 7.54
Rectum 86 43.22
doi:10.1371/journal.pone.0110587.t003
Visceral Fat and Colorectal Cancer
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The precise mechanisms that explain the relationship between
visceral adiposity and CRC remain unclear. However, we suggest
some possible mechanisms based on our results. First, visceral
adipocyte-secreted proinflammatory cytokines and adipokines may
induce a protumourigenic status. Chronic inflammation promotes
carcinogenesis by several mechanisms, including the enhancement
of cancer cell proliferation and angiogenesis [19]. Previous studies
have shown that visceral adipocytes secrete higher levels of
proinflammatory cytokines, including interleukin 6 (IL-6) and
tumour necrosis factor-alpha (TNF-a) [20]. Increased levels of
these cytokines induce a protumourigenic environment [21].
Altered adipokine secretion may also affect colorectal carcinogen-
esis. For example, adiponectin which exhibits anti-tumour
characteristics through anti-inflammatory and proapoptotic ac-
tions [22] shows a negative correlation with visceral fat mass [23].
Furthermore, lower adiponectin levels have been reported in CRC
patients [24,25]. Therefore, systemic chronic inflammation and
altered metabolic function may serve as a link for the association
between visceral obesity and CRC.
Insulin resistance is another factor that supports the association
between visceral obesity and CRC. The correlation between
visceral adipose tissue and insulin resistance is well established
[26]. Lipolysis is more active in visceral adipose tissue than in
subcutaneous adipose tissue, which results in the insulin resistance
status being characterized as hyperinsulinemia [27]. Hyperinsu-
linemia is known to increase the risk of cancers, including CRC
[28], and the prevalence of CRC is higher in Type II DM patients
[29]. Insulin directly stimulates colorectal carcinogenesis by
activating the anti-apoptotic and mitogenic cellular signalling
pathways [22]. Furthermore, the role of insulin in regulating
insulin-like growth factor (IGF) axis activity is also related with the
tumourigenic effect of insulin. Chronic hyperinsulinemia inhibits
the production of IGF-binding protein 1 (IGFBP-1) and IGFBP-2,
which results in the increased bioavailability of IGF-1 [30]. IGF-1
acts as a procarcinogen by enhancing tumour cell proliferation
and decreasing cell death [31]. These results collectively suggest
that the increased insulin resistance induced by visceral adiposity
may be associated with an increased risk of CRC.
Figure 1. Comparison of the prevalence of colorectal cancer
according to visceral fat tertiles before propensity score
matching (Figure1-(A)). Comparison of the prevalence of colorectal
cancer according to visceral fat tertiles after propensity score matching
(Figure1-(B)). P-value was derived using the Cochran-Armitage trend test.
doi:10.1371/journal.pone.0110587.g001
Table 4. Odds ratios and 95% confidence intervals for the prevalence of colorectal cancer according to visceral fat area tertiles
before propensity score matching.
Visceral fat area tertiles, OR (95% CI)
Model Q1 (19.30–67.01) N=271 Q2 (67.10–96.26) N=273 Q3 (96.30–256.20) N=271
Colorectal cancer
Model 1a 1.00 1.01(0.71–1.40) 2.47(1.72–3.55)
Model 2b 1.00 0.82(0.55–1.23) 1.80(1.12–2.91)
Colon cancer
Model 1a 1.00 0.80(0.54–1.19) 2.09(1.39–3.13)
Model 2b 1.00 0.66(0.41–1.06) 1.46(0.84–2.52)
Rectal cancer
Model 1a 1.00 1.34(0.87–2.06) 3.13(2.00–4.88)
Model 2b 1.00 1.13(0.68–1.88) 2.18(1.22–3.91)
Stage I, II
Model 1a 1.00 0.88(0.56–1.37) 2.58(1.66–4.01)
Model 2b 1.00 0.61(0.37–1.04) 1.59(0.89–2.83)
Stage III, IV
Model 1a 1.00 1.08(0.74–1.59) 2.40(1.60–3.59)
Model 2b 1.00 1.04(0.65–1.67) 1.85(1.06–3.21)
doi:10.1371/journal.pone.0110587.t004
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In addition, the direct effect of visceral adiposity on the
development of CRC also should be considered. Recently,
Huffman et al. demonstrated the effect of visceral fat on the
development of intestinal tumours, independent of known
metabolic mediators [32]. Surgical removal of the visceral fat
mass significantly reduced the risk of intestinal cancer in female
mice; however, it failed to increase the levels of adiponectin and
reduce the level of glucose, leptin, chemokines, and total adiposity.
This result suggests that visceral adiposity, at least in part, might
directly affect carcinogenesis in the gastrointestinal (GI) tract,
independent of insulin resistance or inflammatory adipocytokines.
Further experimental studies are needed to elucidate the precise
mechanism by which visceral adiposity affects the prevalence of
CRC.
Our study demonstrated a significant relationship between
visceral obesity and CRC in females in contrast to previous
findings that showed relatively weak or no relationship between
CRC and visceral obesity in female group [33–35]. However these
studies have some limitations that most studies did not adjust the
menopausal status and hormone replacement status that may
affect the relationship between visceral obesity and CRC. For
example Tobias et al [8]. have reported a significant relationship
between CRC risk and the waist-hip ratio only in postmenopausal
women who had not used HRT compared to HRT users. Because
our data were obtained from postmenopausal women without
HRT, our results may reflect the association of visceral obesity and
CRC after minimizing the countering beneficial effects of
exogenous oestrogen replacement. Additionally, many previous
studies have shown a significant association between the risk of
CRC and body composition, including waist circumference and
waist: hip ratio in males [8,36]. Therefore, although we only
investigated the relationship between CRC and visceral obesity in
females, it is possible that these significant relationships also exist
in the male population. Large-scale prospective studies are
required to examine the precise roles of gender in relation to
cancer prevalence and visceral obesity.
Our study has several limitations. First, the cross-sectional
design cannot establish a causal relationship between CRC and
visceral fat area. Although our hypothesis suggested that visceral
obesity might induce a higher risk of CRC, further prospective
interventional studies are needed to elucidate this relationship.
Second, we studied a small number of women who visited a single
hospital. Therefore, our results do not allow for a generalization of
the population at large. Third, we could not compare the levels of
proinflammatory cytokines and adipokines that may act as
important mediating factors because we used the data from the
patients who visited the hospital for health check-up or for
preoperative measurement. However, our results showed signifi-
cantly higher WBC counts in the CRC group compared with the
control group, which reflect the systemic inflammatory status of
the CRC cells. Finally, due to the retrograde data collection
method, clinically important variables, such as socio-economic
status (including education and household income), could not be
adjusted and may affect our results.
In conclusion, our results demonstrate that visceral adiposity is
independently associated with the prevalence of CRC in Korean
women. Although we could not determine causality, our results
collectively suggest that visceral obesity, as well as total obesity,
may be associated with the risk of CRC. Further interventional
prospective studies with larger sample sizes are required to
understand the causal relationship between visceral adiposity and
the prevalence of CRC, as well as to determine the benefits of
controlling visceral obesity for reducing CRC risk.
Table 5. Odds ratios and 95% confidence intervals for the prevalence of colorectal cancer according to visceral fat area tertiles
after propensity score matching.
Visceral fat area tertiles, OR (95% CI)
Model Q1 (19.30–67.98) N=132 Q2 (68.00–93.23) N=133 Q3 (93.30–246.60) N=133
Colorectal cancer
Model 1a 1.00 1.86 (1.10–3.13) 3.47 (2.01–5.98)
Model 2b 1.00 1.60 (0.81–3.14) 2.96 (1.38–6.33)
Colon cancer
Model 1a 1.00 1.43 (0.74–2.74) 3.58 (1.71–7.50)
Model 2b 1.00 1.09 (0.45–2.60) 3.47 (1.24–9.68)
Rectal cancer
Model 1a 1.00 2.90 (1.19–7.11) 3.76 (1.60–8.83)
Model 2b 1.00 3.54 (0.97–12.91) 4.15 (1.05–16.34)
Stage I, II
Model 1a 1.00 1.34 (0.40–4.41) 2.70 (0.62–11.63)
Model 2b 1.00 2.82 (1.19–6.67) 3.64 (1.41–9.39)
Stage III, IV
Model 1a 1.00 1.40 (0.71–2.74) 3.32 (1.70–6.48)
Model 2b 1.00 1.93 (0.77–4.89) 3.80 (1.39–10.40)
OR: odds ratio; CI: confidence interval.
aunadjusted.
badjusted for subcutaneous fat area, mean blood pressure, fasting glucose, total cholesterol, creatinine, aspartate aminotransferase (AST), and alanine aminotransferase
(ALT) and white blood cell (WBC) counts.
OR (95% CI) were derived using conditional logistic regression test.
doi:10.1371/journal.pone.0110587.t005
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